Agilent Technologies Inc. (A) said that the U.S. Food and Drug Administration has
approved the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic or CDx
to identify patients with non-small cell lung cancer who are appropriate for
first-line monotherapy with KEYTRUDA or pembrolizumab on the Dako Omnis platform.
Dako Omnis is Agilent's fully automated, walk-away solution for staining
tumor samples that provides a flexible, high-throughput diagnostic service
integrated into the core of the laboratory workflow.
Lung cancer is the leading cause of cancer-related mortality in the United
States, with an estimated incidence of 142,000 deaths in 2019 alone.
For comments and feedback contact: editorial@rttnews.com
Business News